Previous view $160M-$180M. Raises FY25 Cell Engineering revenue view to $117M-$137M from $110M-$130M. Backs FY25 Bisecurity revenue view at least $50M. Ginkgo updated its previously issued guidance solely to reflect the impact of the previously mentioned $7M non-cash deferred revenue release in Q1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA: